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Abstract- Phenylketonuria is one of the most important congenital disorders and an autosomal recessive 
metabolic disease that can cause irreversible brain damages, mental retardation, and cognitive disorders if left 
untreated. In order to reduce the genetic abnormalities caused by this metabolic disease, screening programs 
are implemented. The quality of the program must be properly assessed to achieve the objectives of this 
program if promoting children's health is of concern. The descriptive-analytic method is adopted here to 
assess the phenylketonuria screening program in practice in Chaharmahal and Bakhtiari province since 2012 
and analyze the incidence and program coverage. The quality of the screening program is assessed through 
analyzing the time of diagnosis, beginning of the treatment and the healthcare centers’ facilities with 
checklists. The parental and the staff awareness is assessed through knowledge measuring questionnaires. 
Cumulative incidence of phenylketonuria in Chaharmahal and Bakhtiari province from 2012 to 2015, is 1 in 
every 6662 live births. The program coverage across the region is 100%. The recorded on-time sampling 
index before 5 days of age, indicate 84.6 % in 2015 from 80% in 2012. The treatment begun before the 
newborn 4 weeks was over in all cases. Program sensitivity was 100 %, and its specificity was 99.9%. Staff 
awareness is fair with no impact on parental awareness. General quality of the screening program is 
appropriate, and as to sensitivity and on-time curing specificity, higher staff and parental awareness 
supervision are recommended as well. 
© 2018 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(1):49-55. 
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Introduction 
 
Genetic and congenital abnormalities in the first 
month of birth are the main causes of body organs 
defects and death in newborns. Every year, around 7.6 
million children are born to the world with genetic or 
congenital abnormalities 90% of whom belong to 
countries with a low per capita income (1).  
The heavy burden caused by the neonatal diseases 
has made the states to plan and implement a screening 
program to diagnose neonatal and other types of 
metabolic diseases (2).  
Phenylketonuria is a recessive autosomal disease 
caused by the deficiency of Phenyl Alanine 
Hydroxylases (PAH) enzyme and an increase in body 
Phenylalanine, and if not treated, leads to mental 
disorders (3-4). 
The outbreak ratio of this disease varies from 1:3000 
to 1:60.000 across the nation (5-6). 
According to the findings of the screening program 
conducted on 630.000 newborns under the supervision 
of 6 medical universities of 3 big provinces of Iran: 
Tehran, Fars, and Mazandaran during 1997-2010 the 
outbreak ratio of Phenylketonuria is 1:8000 (5). 
As determined by the study carried out in the city of 
Isfahan, 2% (36 persons) of the 1611 mentally retarded 
patients who are kept in sanitariums suffer from 
Phenylketonuria (7). 
In several other studies, this percentage is 
emphasized, and in some cases, it reaches 3% (8-9). 
While the population of Iran is less than one-fourth 
of the population of USA, there exist 6 million disabled 
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in both the countries. If the disease is not diagnosed and 
treated during the first year of birth, the child’s IQ 
capacity may reduce by 50%, and it may cause problems 
in future treatments (10-11). 
The marriages taking place within immediate family 
relatives increase the outbreak of the disease as well. 
The irreversible effects of this disease on the brain can 
be prevented through on-time diagnosis and a screening 
program followed by getting the treatment diet regime 
and controlling the Phenylalanine level in the blood (11-
12-13); otherwise, families would face heavy financial 
problems. 
The inability to afford the costly diet of the disease is 
a serious problem which many families of 
Phenylketonuria newborns have to face (12-13). Much 
of the state budget is planned to cover some of the 
expenses of the treatment, rehabilitation, maintenance 
and special diet of the patients despite the shortage of 
resources in the healthcare sector (10-13). 
The screening of newborns at birth and the related 
healthcare sector the burdens on the state; therefore, 
assessing the efficiency and effectiveness of the 
screening program in the healthcare sector as a health 
factor is essential. In order to enhance the quality of 
services and to economize, the organizations have to 
include the assessment process in their schedules and 
conduct the implementation in a scientific and 
technological manner (14-15).  
By implementing the screening program on 
newborns throughout the nation, with the objective of 
accomplishing almost 100% coverage and completing 
the studies on other types of metabolic diseases together 
with adopting appropriate plans by determining the 
outbreak and related costs’ level, it may be possible to 
incorporate the screening program of other diseases in 
the healthcare sector.  
In order to achieve the objectives of this program 
and promote health in families, the accountability and 
high quality of the screening program must be proved. 
In this study, attempt is made to assess the different 
parts of the program in Chaharmahal and Bakhtiari 
province, and apply the findings in determining the 
strong and weak points of the program and adopting 
policies to remove the weak point and promote the 
strong point.  
  
Materials and Methods 
 
Participants  
In 2015, 200 workers from different healthcare centers 
participated in a descriptive-analytical study subject to 
conditions of at least 6 months of work experience in 
healthcare centers and willingness to participate. To begin 
with, with respect to every city’s population the quota of 
each city is determined on a random sampling basis. The 
participants consist of 10 workers from Koohrang, 16 
from Kiar, 15 from Ardal, 40 from Lordegan, 24 from 
Farsan, 25 from Boroojen and 70 from Shahrekord, 
Saman and Ben. The participants are required to answer 
the knowledge assessment questionnaire composed of 20 
questions, and each correct answer equals to one point, 
that is, a ranking of 0-20. The validity of the questionnaire 
is confirmed by the experts in a scientific manner. In 
order to assess the reliability of the questionnaire a pilot 
study is conducted and the correlation coefficient 0.76 is 
obtained.  
The count of the diagnosed and undiagnosed patients 
is determined based on the information available in the 
healthcare center of the province. Since the beginning of 
this program, the positive cases of the reference 
laboratory which proved a negative result in the next 
examinations are annulled. The parents are required to 
answer the knowledge and care regarding the newborns 
with Phenylketonuria in the questionnaire in accordance 
with the census. This questionnaire is composed of 16 
questions, and each correct answer is worth 1.25 points, 
thus a ranking from 0-20. The validity of the 
questionnaire is confirmed by the experts based in a 
scientific manner. In order to assess the reliability of the 
questionnaire the split-half method is applied and the 
correlation coefficient 0.68 is obtained.  
In the program reference laboratories, the 200 
Guthrie card samples collected from the healthcare 
centers are examined. The quality of sample collecting 
process is assessed through a reference to the thyroid 
screening program checklist (16).  
The availability of the materials necessary for 
sample collecting process consisting of Guthrie card, 
Lancet, alcohol pad and the forms used in healthcare 
centers at least for the past one month are assessed.  
The data is assessed by SPSS software, the Relative 
Frequency is applied for the description and for the 
analysis of the Independent t-test, and Pearson 
Correlation Coefficient are applied. 
 
Results 
 
In this study, the findings obtained from the 
implementation of Phenylketonuria screening program 
beginning June 2012 and ending June 2015 throughout 
the nation are analyzed in Chaharmahal and Bakhtiari 
province and tabulated in Table 1. 
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Table 1. The distribution of Phenylketonuria in the four consecutive years 
Year Phenylketonuria cases Live Births 
2012 1 13022 
2013 4 19612 
2014 3 19753 
2015 3 20893 
 
 
The cumulative outbreak ratio of the disease in the 
four consecutive years is 1:6662 live births. From the 20 
cases of Phenylketonuria, 9 cases were diagnosed before 
the implementation of the program, 11 cases during the 
program and 2 cases were born dead; therefore, the 
frequency of Phenylketonuria consists of 18 patients.  
Since the beginning of the program, during the four 
consecutive years, heel blood samples are collected from 
each newborn, and the coverage of the program is at 
100%; however, the on-time sample collecting index 
(sample collecting in the first 5 days of birth) shows a 
different result in the four consecutive years. 
 
Table 2. On time sample collecting index 
Year 
On time sample collecting 
percentage 
Delayed sample collecting 
percentage 
2012 80% 20% 
2013 81% 19% 
2014 83% 17% 
2015 84.6% 15.4% 
 
The treatment for each of the Phenylketonuria 
newborns during the four consecutive years began 
before they reached four weeks of age with differences 
in beginning time of the treatment. 
 
Table 3. Treatment beginning time 
Year Less than 2 weeks 2-3 weeks 
2012 (1)100% 0 
2013 (2)50% (2)50% 
2014 (1)33.3% (2)66.7% 
2015 (2)66.7% (1)33.3% 
 
No cases of Transient hyperphenylalaninemia are 
observed during the implementation of the program. 
Seven false positive cases of ELISA are revealed: one in 
2012, one in 2013, 2 in 2014 and 3 in 2015 which are 
then rejected after being identified as negative through 
HPLC test. Therefore, the sensitivity of the program 
during the four consecutive years is 100% with 99.9% 
specificity. The negative predictive value in the four 
consecutive years is 100%, but the positive predictive 
value varies in each consecutive year by 50% in 2012, 
80% in 2013, 60% in 2014 and 50% in 2015. 
Throughout the program, the negative false result is 
registered at 0% and the positive false result at less than 
0.01%.  
The obtained positive and negative predictive values 
of the HPLC test is 100%, that is, all the positive cases 
have the disease, and all the negative cases don’t have 
the disease.  
According to the assessments conducted by the 
provincial Health Department, the instructional texts and 
resources were available in all the healthcare centers to 
train the personnel.  
The average age of the 200 participants is 
39.12±7.79. The average working experience of the 
workers is 16.69 years with 8.88 standard deviations 
(SD), and the mean score of knowledge from 0 to 20 
scores is 10.88 with 4.92 (SD). From the 200 
participants of the study, 117 are female (58%), and 83 
are male (41.5%) workers.  
There exists no statistical significance between the 
mean score of knowledge and the average age of the 
participants; P=0.518. 
There exists no statistical significance between the 
mean score of knowledge and the working experience of 
the participants; P=0.336. 
There exists no statistical significance between the 
mean score of knowledge and the gender of the 
participants; P=0.352. 
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Table 4. The mean score of knowledge 
Gender Knowledge mean SD P 
Female 11.1 4.8 
0.352 
Male 10.14 5 
 
The parents of the newborn with Phenylketonuria are 
provided with information on the disease by the hospital 
and healthcare center personnel. In one case the parents 
gathered the necessary information from the internet. 
The mean score of knowledge of parents within 0 to 20 
is 15.7 with 1.1 (SD).  
In the 20 cases of this study, two cases of the patients 
are first relatives of the first degree (10%), 9 cases are 
relatives of the second degree or higher (45%), and the 
other 9 cases are not relatives (45%). 
As to the average time regarding sample delivery to 
the laboratory not all were sent immediately but within 
48 hrs. 
The positive cases are reported by phone to the 
sample collecting centers, and the negative cases are 
reported in written form to the centers within 2 weeks.  
The sample collecting process in the healthcare 
centers is checked in terms of quality, Table 5. 
 
Table 5. Checking the sample collecting process quality 
Question Yes No 
Were 4 circles of Guthrie papers completed with blood sample 124(62%) 76(38%) 
Were the samples in circular shape? 86(43%) 114(57%) 
Were the blood spots diameter more than 5 mm? 14(7%) 186(93%) 
Whether there were more than one blood stains in each circle? 185(92.5%) 15(7.5%) 
Were the blood spots without the fingerprint? 200(100%) 0 
Did the blood spots look identical on both sides of the cards? 189(94.5%) 11(5.5%) 
Were the blood spots overlap? 188(94%) 12(6%) 
 
 
Discussion 
 
The Phenylketonuria screening program for 
newborns in Chaharmahal and Bakhtiari province is a 
process going on since 2012. Since the begging of the 
program until 2015, 73280 newborns have been exposed 
to the screening program, and the 11 diagnosed cases of 
PKU are under treatment.  
Here, it is revealed that the screening program 
coverage in the province is 100%. The screening 
program coverage of Brazil varies in different years: 
72% in 2003, 78.28 in 2005 and 78.93 in 2007 (17-18-
19). In Parana, the coverage increased from 86.99% to 
99.01% in 1996-2001 (20). In a study conducted in 
France, it is revealed that the screening program 
coverage increased in a progressive manner and in 1980 
reached its maximum percentage (21). The outstanding 
coverage percentage in Chaharmahal and Bakhtiari 
province is the outcome of the excellent work performed 
in the healthcare centers of the nation.  
Based on the findings of this study, the outbreak 
ratio of Phenylketonuria in Chaharmahal and Bakhtiari 
province is 1:6662 in live births. This ratio varies in 
different countries: the lowest outbreak ratio is found in 
Finland (1:200000) and Japan (1:125000) which is due 
to the genetics and the highest outbreak ratio is found in 
Arabian countries (more than 1:5000) and Turkey 
(1:2600) where the marriages take place within 
immediate family relatives (22). The outbreak ration of 
the disease is 1:8690 in Brazil and 1:10000 in Europe 
(23-24-25). Among the European countries, the outbreak 
ratio of the disease is surprisingly high in Ireland and 
Western Scotland (1:4500) making it one the highest 
ratios (26). In China, this ratio is 1:18000 (27). 
In a study conducted in Fars province in 2010, it is 
revealed that the outbreak ratio of PKU in Shiraz and 
Eghlid is 1:4698 and 1:384, respectively, which is due to 
the existence of a pathogen genetic factor (28). 
In 8633 births in various hospitals of Tehran, the 
outbreak ratio is estimated as 1.1:10000. In 1544 
newborns with the symptoms of the metabolic disease, 
the outbreak ratio is 1:3672 (29). In the city of Isfahan, 
the outbreak ratio among the 1611 mentally retarded 
patients is 20% (36:1611), (30).  
Through the comparison of the findings of various 
studies, it can be deduced that the outbreak ratio in 
Chaharmahal and Bakhtiari province is close to the 
national average. The outbreak ratio in this province is 
high due to the 100% coverage of the screening 
program and the sensibility and appropriateness of 
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HPLC testing which diagnose all the newborns with 
the disease.  
According to this study, the on-time sample 
collecting index (first 3-5 days of birth) is enhanced 
from 80% to 84.6% in 2012-2015. Iran is in a better 
position when compared to other nations, with respect to 
the sample collecting timing.  
In a study conducted in Brazil in 2014 it is reported 
that the filter paper collecting process took 2-30 days 
and in 26.74% of the cases, the screening program is 
conducted on 2-6 years old children (23). The average 
age of the newborns who were exposed to the screening 
program in Mexico is 18 days (31). 
According to this study, the treatment for the PKU 
newborns diagnosed in the screening program began 
within 4 weeks: 6 newborns less than 2 weeks (54.5%) 
and 5 newborns in their 2-3rd weeks (45.5%). In the 
study conducted in Brazil (2004), in 71.9% cases, the 
treatment began in 30 days and in 15.6% after 60 days 
(32). The appropriate timing in collecting samples and 
beginning the treatment in the province is the outcome 
of the consistency and the excellent management.  
The sensibility and significance of HPLC is 100% in 
this province. The positive predictive value of ELISA 
testing varies in four consecutive study years, which is 
adjusted through HPLC. The total significance of the 
program is 99%.  
In the study carried out in France, from the 21.5 
million newborns exposed to the PKU screening 
program with a 99.3% sensibility. Two newborns were 
not exposed to the Guthrie test, 2 other patients 
disappeared before the testing, and in case of 6 
newborns a false negative result is detected (33). Several 
other studies reported a similar ratio of false negative 
results with diverse sensitivities ranging from 98% to 
99.2% (34-35-36). According to various studies, the 
ratio of false negative results is reduced over time (37). 
The high sensitivity and significance of the program in 
this study is the outcome of the appropriate management 
system and the reliable reference laboratories with 
experienced personnel. 
In this study, more than 50% of the newborns of the 
diagnosed cases are the offspring of the marriages taking 
place within immediate family relatives. In the studies 
conducted in Mashhad and Mazandaran provinces, 80% 
(high) and 60% (moderate) of the parents are relatives, 
respectively. In some other studies, 82% of the parents 
are not relatives (38-39-40).  
Considering the existence of the disease in other 
members of the family, two newborns suffering from the 
disease are sisters in this study, which corresponds to the 
studies of 12% in Mashhad, 10% in Shiraz, 12% in 
Mexico (28-29-30-31).  
The mean score of knowledge about Phenylketonuria 
screening program of the healthcare center workers is 
average, which is corresponds to the study of 
hypothyroid screening program in newborns. However, 
this score is a warning in order to revise the worker 
training programs (16). 
From the findings of this study, it is deduced that the 
healthcare center workers did not play an important role 
in enhancing the knowledge of the parents about the 
disease and the treatment procedure. This may be due to 
the fact that the workers are not trained enough and 
refuse to give instructions to the parents of the newborns 
and do not collaborate with the healthcare centers after 
the diagnosis of the disease and enrolled at the hospital 
care.  
Although the knowledge score of the workers is not 
high, all of the newborns are diagnosed and cured which 
is the outcome of conducting the screening in an 
appropriate manner and the excellent collaboration of 
the laboratory and hospital personnel.   
The quality of the sample collecting procedure is far 
from ideal, but based on the high sensitivity and 
significance of the program the least requirements to 
collect the samples are observed. Although the required 
standard for filling out the four circles is not observed, 
the 5mm and 3mm samples provided the least necessary 
volume. 
Despite the existing problems, the materials 
necessary to collect the samples in the healthcare centers 
are provided, and there exists a direct cooperation 
among healthcare centers’ personnel. 
Attempt is made here to determine the causative 
weaknesses of the Phenylketonuria screening program in 
an objective manner. 
In accordance with the findings of this study, the 
quality of the Phenylketonuria screening program in 
the province is met in terms of collecting the samples, 
on- time diagnosis and immediate treatment operations. 
The knowledge score of the healthcare center workers 
is insufficient, which affects the efficiency of the 
program. Although the knowledge score of the parents 
is higher than the average, care must be taken in order 
to improve the knowledge score of the parents and the 
workers. The parents are required to collaborate with 
the healthcare centers, and the mothers must get the 
required instructions regarding the program before 
giving birth; therefore, the program manager is 
required to have more control over the health care 
center workers.  
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